Revenue Recognition - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 28, 2019	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024
Disaggregation of Revenue [Line Items]
Deferred revenue		$ 53,861	$ 37,262	$ 41,969	$ 36,592
Product revenues
Disaggregation of Revenue [Line Items]
Approximate percentage of revenue collected within 9 months		90.00%
Billing collection period (in months)		9 months
Extended billing collection period (in months)		6 months
Test Revenue
Disaggregation of Revenue [Line Items]
Increased revenue		$ 61,000	$ 34,300
Decrease in net loss per share ( in dollars per share)		$ 0.43	$ 0.25
BGI Genomics
Disaggregation of Revenue [Line Items]
Agreement term	10 years
Deferred revenue		$ 16,700		$ 16,800
BGI Genomics | Oncology
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation					$ 20,000
Revenue recognized		$ 100	$ 100